Cantor Fitzgerald tells investors in a research note that NeuroPace (NPCE) remains the firm’s best idea for 2025 and represents an attractive ...

Q4 2024 Earnings Call Transcript March 4, 2025 NeuroPace, Inc. beats earnings expectations. Reported EPS is $-0.18, ...

Revenue: US$79.9m (up 22% from FY 2023). Net loss: US$27.1m (loss narrowed by 18% from FY 2023). US$0.93 loss per share ...

Fourth Quarter 2024 Financial Results Total revenue in the fourth quarter of 2024 grew 19% to $21.5 million, compared with $18.0 million in the fourth quarter of 2023. The Company’s revenue growth was ...

MOUNTAIN VIEW, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced ...

Shares of NeuroPace stock opened at $12.95 on Friday. The business’s fifty day simple moving average is $12.69 and its 200 day simple moving average is $9.66. The firm has a market ...

NeuroPace, Inc. (NASDAQ:NPCE), a medical device company specializing in neurological disorders, has been making significant strides in the epilepsy treatment market with its Responsive ...

Quarterly revenue grew 19% year-over-year to $21.5 million in the fourth quarter of 2024 Full year 2024 revenue increased 22% to $79.9 million compared with $65.4 million in 2023; revenue grew ...

Greetings and welcome to NeuroPace Fourth Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation.

NeuroPace, Inc. (NASDAQ:NPCE), a medical device company specializing in neurological disorders, has been making significant strides in the epilepsy treatment market with its Responsive ...

March 04, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for ...